Xalkori(crizotinib)
Xalkori (crizotinib) is a small molecule pharmaceutical. Crizotinib was first approved as Xalkori on 2011-08-26. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against ALK tyrosine kinase receptor. In addition, it is known to target hepatocyte growth factor receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| respiratory tract diseases | D012140 |
Trade Name
FDA
EMA
Xalkori
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Crizotinib
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XALKORI | CV Sciences | N-202570 RX | 2011-08-26 | 2 products, RLD, RS |
| XALKORI | CV Sciences | N-217581 RX | 2023-09-07 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| xalkori | New Drug Application | 2024-07-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| non-small-cell lung carcinoma | — | D002289 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CRIZOTINIB, XALKORI, PF PRISM CV | |||
| 2029-07-14 | ODE-407 | ||
| 2028-01-14 | ODE-328 | ||
| 2025-07-14 | I-897 | ||
| 2024-01-14 | I-852 | ||
| 2023-03-11 | ODE-111 | ||
HCPCS
No data
Clinical
Clinical Trials
172 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 18 | 36 | 22 | 2 | 20 | 89 |
| Lymphoma | D008223 | — | C85.9 | 4 | 9 | 2 | 2 | 1 | 16 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 3 | 5 | — | 3 | — | 10 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | 3 | — | 1 | — | 5 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 18 | 29 | 15 | — | 13 | 67 |
| Neoplasms | D009369 | — | C80 | 12 | 18 | 2 | — | 5 | 33 |
| Carcinoma | D002277 | — | C80.0 | 2 | 4 | 2 | — | — | 8 |
| Melanoma | D008545 | — | — | 1 | 5 | 1 | — | 1 | 6 |
| Uveal neoplasms | D014604 | EFO_1001230 | — | 1 | 3 | 1 | — | — | 3 |
| Gene rearrangement | D015321 | — | — | — | 1 | 1 | — | — | 2 |
| Plasma cell granuloma | D006104 | — | — | — | 2 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 3 | 3 | — | — | 1 | 6 |
| Multiple myeloma | D009101 | — | C90.0 | — | 6 | — | — | — | 6 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | 5 | — | — | — | 6 |
| Adenocarcinoma | D000230 | — | — | 1 | 4 | — | — | 1 | 6 |
| Colorectal neoplasms | D015179 | — | — | 2 | 4 | — | — | 1 | 6 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 3 | — | — | 1 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 4 | — | — | — | 5 |
| Hematologic neoplasms | D019337 | — | — | — | 4 | — | — | — | 4 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 3 | — | — | — | 3 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 1 | — | — | — | 3 |
Show 51 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 14 | — | — | — | — | 14 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | 1 | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Large cell carcinoma | D018287 | — | — | 1 | — | — | — | — | 1 |
| Diffuse intrinsic pontine glioma | D000080443 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | — | — | — | — | 1 | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | — | — | — | — | 1 | 1 |
| Acute disease | D000208 | — | — | — | — | — | — | 1 | 1 |
| Lymphoid leukemia | D007945 | — | C91 | — | — | — | — | 1 | 1 |
| Fibrinolysis | D005342 | — | — | — | — | — | — | 1 | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 1 | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Crizotinib |
| INN | crizotinib |
| Description | Crizotinib is a 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) It has a role as an antineoplastic agent, a biomarker and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is an enantiomer of an ent-crizotinib. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl |
Identifiers
| PDB | — |
| CAS-ID | 877399-52-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL601719 |
| ChEBI ID | 64310 |
| PubChem CID | 11626560 |
| DrugBank | DB08865 |
| UNII ID | 53AH36668S (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
MET
MET
Organism
Homo sapiens
Gene name
MET
Gene synonyms
NCBI Gene ID
Protein name
hepatocyte growth factor receptor
Protein synonyms
HGF receptor, HGF/SF receptor, Proto-oncogene c-Met, Scatter factor receptor, SF receptor, Tyrosine-protein kinase Met
Uniprot ID
Mouse ortholog
Met (17295)
hepatocyte growth factor receptor (P16056)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Xalkori – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 55,793 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,261 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use